We Can Medicines Co., Ltd.(TW:6929)
NT$21.15+0.30 (+1.44%)
TW:6929
We Can Medicines Co., Ltd. financials statements
NT$21.15
At close:+0.30 (+1.44%)
We Can Medicines Co., Ltd. (6929) Ratios
We Can Medicines Co., Ltd. Ratios
TW:6929's free cash flow for Q2 2026 was NT$85.26M. For the 2026 fiscal year, TW:6929's free cash flow was decreased by NT$-5.70M and operating cash flow was NT$90.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.53 | 1.59 | 1.24 | 1.28 | 1.28 |
| Quick Ratio | 0.64 | 0.67 | 0.49 | 0.52 | 0.53 |
| Cash Ratio | 0.26 | 0.33 | 0.15 | 0.24 | 0.26 |
| Solvency Ratio | 0.13 | 0.13 | 0.14 | 0.20 | 0.17 |
| Operating Cash Flow Ratio | 0.27 | 0.28 | 0.13 | 0.39 | 0.59 |
| Short-Term Operating Cash Flow Coverage | 33.81 | 35.40 | 0.97 | 26.78 | 42.93 |
| Net Current Asset Value | NT$ -480.10M | NT$ -504.81M | NT$ -752.98M | NT$ -629.51M | NT$ -530.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.40 | 0.46 | 0.41 | 0.41 |
| Debt-to-Equity Ratio | 1.14 | 1.11 | 1.62 | 1.34 | 1.32 |
| Debt-to-Capital Ratio | 0.53 | 0.53 | 0.62 | 0.57 | 0.57 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.10 | 0.14 | 0.15 | 0.18 |
| Financial Leverage Ratio | 2.84 | 2.76 | 3.50 | 3.25 | 3.23 |
| Debt Service Coverage Ratio | 7.62 | 8.32 | 1.88 | 11.64 | 10.65 |
| Interest Coverage Ratio | -2.66 | -1.83 | 1.82 | 7.55 | 3.69 |
| Debt to Market Cap | 0.09 | 0.08 | 0.07 | 0.04 | 0.09 |
| Interest Debt Per Share | 27.18 | 29.32 | 33.54 | 27.08 | 22.90 |
| Net Debt to EBITDA | 3.77 | 3.25 | 3.60 | 2.15 | 2.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 23.20% | 33.77% | 32.77% | 33.66% | 32.80% |
| EBIT Margin | -2.11% | -0.64% | 1.44% | 4.25% | 1.90% |
| EBITDA Margin | 7.84% | 8.82% | 10.29% | 11.92% | 9.56% |
| Operating Profit Margin | -2.11% | -1.53% | 1.37% | 4.36% | 1.91% |
| Pretax Profit Margin | -2.27% | -1.48% | 0.69% | 3.67% | 1.39% |
| Net Profit Margin | -2.27% | -1.44% | 0.47% | 3.03% | 1.39% |
| Continuous Operations Profit Margin | -2.27% | -1.44% | 0.47% | 3.03% | 1.39% |
| Net Income Per EBT | 100.02% | 97.69% | 68.53% | 82.60% | 100.00% |
| EBT Per EBIT | 107.60% | 96.34% | 50.63% | 84.03% | 72.76% |
| Return on Assets (ROA) | -2.46% | -1.53% | 0.52% | 3.88% | 1.76% |
| Return on Equity (ROE) | -6.98% | -4.23% | 1.81% | 12.64% | 5.67% |
| Return on Capital Employed (ROCE) | -3.35% | -2.32% | 2.35% | 8.60% | 3.72% |
| Return on Invested Capital (ROIC) | -2.97% | -2.04% | 1.35% | 6.31% | 3.30% |
| Return on Tangible Assets | -2.46% | -1.53% | 0.52% | 3.89% | 1.76% |
| Earnings Yield | -4.73% | -2.82% | 0.35% | 2.64% | 2.11% |
| Efficiency Ratios | |||||
| Receivables Turnover | 13.66 | 15.07 | 11.76 | 19.43 | 18.20 |
| Payables Turnover | 4.83 | 4.27 | 3.90 | 4.29 | 4.34 |
| Inventory Turnover | 2.93 | 2.54 | 2.70 | 3.17 | 3.22 |
| Fixed Asset Turnover | 2.19 | 2.09 | 2.06 | 2.41 | 2.43 |
| Asset Turnover | 1.08 | 1.06 | 1.09 | 1.28 | 1.26 |
| Working Capital Turnover Ratio | 6.17 | 8.28 | 12.47 | 13.96 | 9.90 |
| Cash Conversion Cycle | 75.98 | 82.16 | 72.55 | 48.71 | 49.43 |
| Days of Sales Outstanding | 26.72 | 24.22 | 31.04 | 18.79 | 20.06 |
| Days of Inventory Outstanding | 124.79 | 143.43 | 135.06 | 115.02 | 113.53 |
| Days of Payables Outstanding | 75.53 | 85.49 | 93.55 | 85.09 | 84.16 |
| Operating Cycle | 151.51 | 167.65 | 166.10 | 133.80 | 133.59 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.68 | 6.02 | 3.50 | 8.67 | 11.43 |
| Free Cash Flow Per Share | 4.89 | 4.42 | 1.15 | 5.59 | 2.86 |
| Dividend Paid and CapEx Coverage Ratio | 7.20 | 3.21 | 1.49 | 2.82 | 1.33 |
| Capital Expenditure Coverage Ratio | 7.20 | 3.76 | 1.49 | 2.82 | 1.33 |
| Operating Cash Flow Coverage Ratio | 0.21 | 0.21 | 0.11 | 0.33 | 0.51 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.08 | 0.04 | 0.10 | 0.16 |
| Free Cash Flow Yield | 14.22% | 11.44% | 1.07% | 5.89% | 6.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -21.10 | -35.46 | 289.19 | 37.96 | 47.42 |
| Price-to-Sales (P/S) Ratio | 0.48 | 0.51 | 1.37 | 1.15 | 0.66 |
| Price-to-Book (P/B) Ratio | 1.48 | 1.50 | 5.24 | 4.79 | 2.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.03 | 8.74 | 93.29 | 16.97 | 16.11 |
| Price-to-Operating Cash Flow Ratio | 6.06 | 6.42 | 30.61 | 10.95 | 4.02 |
| Price-to-Earnings Growth (PEG) Ratio | -0.43 | 0.09 | -3.39 | 0.24 | -1.75 |
| Enterprise Value Multiple | 9.90 | 9.05 | 16.93 | 11.79 | 9.51 |
| Enterprise Value | 2.50B | 2.61B | 5.44B | 4.64B | 2.54B |
| EV to EBITDA | 9.90 | 9.05 | 16.93 | 11.79 | 9.51 |
| EV to Sales | 0.78 | 0.80 | 1.74 | 1.41 | 0.91 |
| EV to Free Cash Flow | 11.36 | 13.63 | 118.53 | 20.75 | 22.22 |
| EV to Operating Cash Flow | 9.78 | 10.01 | 38.89 | 13.40 | 5.55 |
| Tangible Book Value Per Share | 23.20 | 25.63 | 20.31 | 19.67 | 16.88 |
| Shareholders’ Equity Per Share | 23.30 | 25.79 | 20.40 | 19.79 | 17.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.02 | 0.31 | 0.17 | 0.00 |
| Revenue Per Share | 71.59 | 75.53 | 78.06 | 82.57 | 69.86 |
| Net Income Per Share | -1.63 | -1.09 | 0.37 | 2.50 | 0.97 |
| Tax Burden | 1.00 | 0.98 | 0.69 | 0.83 | 1.00 |
| Interest Burden | 1.08 | 2.31 | 0.48 | 0.86 | 0.73 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.35 | 0.35 | 0.32 | 0.30 | 0.32 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -3.49 | -5.40 | 6.47 | 2.86 | 11.78 |
Currency in TWD
